TABLE 2

IC50 derived from dose-response curves of BTK and TEC occupancy in the MWCL-1 cell line

DrugTime Point (h)BTK IC50 (nM)TEC IC50 (nM)BTK/TEC Selectivitya
Ibrutinib0.52.887.282.53
13.994.181.05
31.061.601.51
Acalabrutinib0.550.8949.360.97
126.1029.381.13
35.4714.012.56
  • a BTK/TEC selectivity is defined as TEC IC50/BTK IC50.